Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akcea Therapeutics Steps Up Commercialization Efforts In Europe

Executive Summary

With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.

You may also be interested in...



Akcea C-Suite Upheaval’s Reasons Unclear, Firm Set To Take In More Ionis Programs

Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.

EU CHMP Backs Three Conditional Approvals & Several Treatment Firsts

Akcea’s Waylivra, Portola’s Ondexxya, BioMarin’s Palynziq, AbbVie’s Skyrizi and Pfizer’s Lorviqua are among new drugs to receive a positive opinion from the EU’s CHMP at its latest monthly meeting.

Quiet Riot? Gene Silencing Candidates Still Ready To Make Noise In Lipid Disorders

Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC124874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel